Global perspective

Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia and bacterial infections, Daiichi Sankyo is also engaged in the development of treatments for thrombotic disorders and focuses on the discovery of novel oncology and cardiovascular-metabolic therapies. more...

Global business strategy

Like other research-based pharmaceutical companies, Daiichi Sankyo is engaged in high-risk/high-return research and development investments. But the growth rates of the pharmaceutical markets in industrialised countries are low. more...

Global key figures

In fiscal year 2012, Daiichi Sankyo increased its net sales from €8.62 billion to €9.31 billion. Operating income rose to €938 million. These results were achieved by about 32,200 employees worldwide. more...

European perspective

In Europe, Daiichi Sankyo is also dedicated to the creation and supply of innovative pharmaceutical products to address the diversified unmet medical needs of patients. In Europe, the company's roots extend back to the 1980s, when both Daiichi and Sankyo established offices in Düsseldorf, Germany. Here, the merger between the two traditional Japanese enterprises took place in 2007. more...

European business strategy

Daiichi Sankyo Europe pursues a strategy of sustainable growth. As part of this strategy, we employ an operating model that systematically places the interests of our stakeholders, customers and patients at the centre of our activities. more...

Production plants

Daiichi Sankyo Europe has two production facilities, both approved by national and international authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMEA) and the German Institute for Drugs and Medical Devices (BfArM) more...